FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.
What happened
FDA inspected the Vietnam drug manufacturing facility from December 15 to 21, 2023. It found that Yahon released OTC ethyl alcohol antiseptic wipes without testing each batch for identity and strength of the active ingredient, did not adequately test incoming ethyl alcohol and benzalkonium chloride, and set a three-year expiry without stability data.
What FDA found
Yahon released OTC drug products, including ethyl alcohol antiseptic wipes, without adequate testing of each batch for identity and strength of the active ingredient before release.
21 CFR 211.165(a)Yahon did not perform adequate identity testing on each lot of ethyl alcohol and benzalkonium chloride used to make its OTC drugs.
21 CFR 211.84(d)(2)Yahon assigned a three-year expiration date to ethyl alcohol antiseptic wipes without stability data to support it.
21 CFR 211.137(a)Yahon’s quality unit did not ensure adequate process validation, cleaning validation, required manufacturing record storage, or reserve sample collection and storage.
21 CFR 211.22
What FDA wants
FDA tells Yahon to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and to state reasons and a completion schedule if it cannot finish. FDA also recommends engaging a qualified CGMP (current good manufacturing practice) consultant.
Who should pay attention
- U.S. distributors and retailers selling Yahon antiseptic wipes
- brands that rely on contract manufacturers for OTC drugs
- quality teams managing supplier qualification and component testing
This is a summary. Read the original letter on fda.gov.